Skip to main content
. 2011 Aug;36(8 Section 2):2–31.

TABLE 7.

Potential Payer-directed Barriers to Applying Best Practice in PIDD

  • Excessive trough-level monitoring

  • Under-appreciation of antibody quality

  • Recommending dosage reductions to achieve “target” trough (no data)

  • Allowing dosing only after a particular IgG threshold is crossed (no data)

  • Requiring proven infections before approving therapy (no data; dangerous in genetic PIDD)

  • Variability in diagnostic criteria and in requirements for initiation of therapy

  • Excessive requests for cessation of therapy

Source: Orange 2011b. Reproduced with permission.